Novel Vector System for Breast Cancer Therapy
Annual rept. 1 Oct 1999-30 Sep 2000
ALABAMA UNIV IN BIRMINGHAM
Pagination or Media Count:
This project is directed towards the development and testing of a novel, controlled release formulation of tumor necrosis factor alpha TNFK in combination with a partially replication defective adenovirus for the regional treatment of breast cancer. In the past year, we have refined our formulations of TNFK so as to be more suitable for ultimate human use. We have also assessed the effects of TNFK with or without adenovirus on the growth of breast cancer cells in vitro. Pilot animal experiments with free TNFK showed that our flank tumor nodule model did respond to this treatment, and therefore could be used to test the novel therapies developed here. An alternative, novel immunotherapy has been developed whereby plasmids encoding chemokines, agents that attract immunomodulatory cells to tissue sites, were shown to be effective in vivo. This strategy will be modified to encapsulate plamsids encoding the adenoviral E1A proteins, and tested head-to-head against the intact adenovirus in the animal experiments planned for the final year of this project.
- Anatomy and Physiology
- Medicine and Medical Research